MYND Life Sciences Announces Shares for Debt Transaction
MYND Life Sciences Announces the Issuance of 4,000,001 Shares at $0.71/share
MYND Life Sciences Announces Successful Conclusion of Debenture Settlement Agreement and Leadership Transition
MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment
MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business
MYND Life Sciences Announces New Director & Update on the Proposed Merger with Cava Healthcare Inc.
MYND Life Sciences Inc. Announces the Appointment of Mr. John Campbell as President and Chief Executive Officer
Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences
MYND Life Sciences Inc. Announces Non-Binding LOI to enable merger with Cava Healthcare Inc.
MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures